Skip to main content

EDITORIAL article

Front. Endocrinol.
Sec. Reproduction
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1516736
This article is part of the Research Topic Advances in the Treatment of Sexual Precocity and Infertility View all 28 articles

Editorial: Advances in the Treatment of Sexual Precocity and Infertility

Provisionally accepted
Dimitrios T. Papadimitriou Dimitrios T. Papadimitriou 1*George Mastorakos George Mastorakos 2Constantine A Stratakis Constantine A Stratakis 3
  • 1 Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
  • 2 Endocrine Unit, Department of Obstetrics and Gynecology, Aretaieion Hospital, Athens, Greece
  • 3 National Institutes of Health (NIH), Bethesda, Maryland, United States

The final, formatted version of the article will be published soon.

    Our topic "Advances in the Treatment of Sexual Precocity and Infertility" addresses critical advancements in pediatric-adolescent endocrinology, reproductive medicine, and gynecology. With genetic precision medicine becoming increasingly important [1], this collection of 27 articles explores the underlying mechanisms of sexual precocity, hypogonadism, infertility [2], and offers novel insights into therapeutic approaches, enhancing both clinical outcomes and quality of life for affected individuals. The research emphasizes innovations in reproductive treatments, personalized medicine, hormonal therapies involving aromatase inhibitors even in early maturing girls with a compromised growth potential [3], and management strategies for conditions like polycystic ovary syndrome (PCOS) [4], poor ovarian response, and hypogonadotropic hypogonadism. Several studies in this collection focus on improving in vitro fertilization (IVF) protocols to optimize pregnancy outcomes while maintaining cost-effectiveness. A multicenter randomized controlled trial comparing a modified GnRH antagonist protocol based on luteinizing hormone (LH) levels with the conventional GnRH antagonist protocol found that both had similar clinical efficacy. However, the modified protocol was more cost-effective, reducing overall financial burden during assisted reproductive technology (ART) cycles https://www.frontiersin.org/articles/10.3389/fendo.2022.922950/full. The exploration of ovulation promotion protocols in young IVF patients with low anti-Müllerian hormone (AMH) levels revealed that the GnRH antagonist protocol yielded better cumulative live birth rates (CLBR) than the progestinprimed ovarian stimulation (PPOS) regimen, particularly for patients with low but not very low AMH

    Keywords: Infertility, precocious puberty, Hypogonadism, Aromatase Inhibitors, in vitro fertilization, personalized medicine, Polycystic Ovary Syndrome

    Received: 24 Oct 2024; Accepted: 13 Nov 2024.

    Copyright: © 2024 Papadimitriou, Mastorakos and Stratakis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dimitrios T. Papadimitriou, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.